Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC · Real-Time Price · USD
2.060
-0.010 (-0.48%)
At close: Nov 7, 2025, 4:00 PM EST
2.100
+0.040 (1.94%)
After-hours: Nov 7, 2025, 7:20 PM EST
Ensysce Biosciences Revenue
Ensysce Biosciences had revenue of $1.37M in the quarter ending June 30, 2025, with 654.38% growth. This brings the company's revenue in the last twelve months to $7.41M, up 415.58% year-over-year. In the year 2024, Ensysce Biosciences had annual revenue of $5.21M with 133.58% growth.
Revenue (ttm)
$7.41M
Revenue Growth
+415.58%
P/S Ratio
0.37
Revenue / Employee
$926,715
Employees
8
Market Cap
6.11M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.21M | 2.98M | 133.58% |
| Dec 31, 2023 | 2.23M | -292.86K | -11.61% |
| Dec 31, 2022 | 2.52M | -1.01M | -28.54% |
| Dec 31, 2021 | 3.53M | -400.01K | -10.18% |
| Dec 31, 2020 | 3.93M | 2.17M | 122.86% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ENSC News
- 4 weeks ago - Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025 - Accesswire
- 2 months ago - Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium - Accesswire
- 2 months ago - Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025 - Accesswire
- 3 months ago - Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC) - GlobeNewsWire
- 3 months ago - Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates - Accesswire
- 3 months ago - Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback - Accesswire
- 4 months ago - Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse - Accesswire
- 4 months ago - Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2 - Accesswire